Advances in Immunotherapy for Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related
deaths in the world. More than half of patients with HCC present with advanced stage, and …
deaths in the world. More than half of patients with HCC present with advanced stage, and …
Recent advances in immunotherapy for hepatocellular carcinoma
S Nakano, Y Eso, H Okada, A Takai, K Takahashi… - Cancers, 2020 - mdpi.com
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death since
most patients are diagnosed at advanced stage and the current systemic treatment options …
most patients are diagnosed at advanced stage and the current systemic treatment options …
Immune checkpoint inhibitor resistance in hepatocellular carcinoma
Z Wang, Y Wang, P Gao, J Ding - Cancer letters, 2023 - Elsevier
The application of immune checkpoint inhibitors (ICIs) has markedly enhanced the treatment
of hepatocellular carcinoma (HCC), and HCC patients who respond to ICIs have shown …
of hepatocellular carcinoma (HCC), and HCC patients who respond to ICIs have shown …
[HTML][HTML] Immune checkpoint inhibitors in hepatocellular cancer: current understanding on mechanisms of resistance and biomarkers of response to treatment
AE Onuma, H Zhang, H Huang, TM Williams… - Gene …, 2020 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy worldwide
and a leading cause of death worldwide. Its incidence continues to increase in the US due to …
and a leading cause of death worldwide. Its incidence continues to increase in the US due to …
[HTML][HTML] Treatment Options for Hepatocellular Carcinoma Using Immunotherapy: Present and Future
H Wei, C Dong, X Li - Journal of Clinical and Translational …, 2024 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is a common cancer, and the body's immune responses
greatly affect its progression and the prognosis of patients. Immunological suppression and …
greatly affect its progression and the prognosis of patients. Immunological suppression and …
Current landscape of immune checkpoint inhibitor therapy for hepatocellular carcinoma
Simple Summary Hepatocellular carcinoma (HCC) is the most common primary hepatic
malignancy, with increasing incidence over the past several decades. The majority of …
malignancy, with increasing incidence over the past several decades. The majority of …
Immunotherapy updates in advanced hepatocellular carcinoma
A Singh, RJ Beechinor, JC Huynh, D Li, F Dayyani… - Cancers, 2021 - mdpi.com
Simple Summary Advanced hepatocellular carcinoma (HCC) carries a grim prognosis,
which has historically been compounded by a lack of available systemic therapies …
which has historically been compounded by a lack of available systemic therapies …
Immunotherapy in hepatocellular carcinoma: is there a light at the end of the tunnel?
Hepatocellular carcinoma (HCC) is the most common primary liver cancer with dismal
prognosis when diagnosed at advanced stages. Surgical resection of the primary tumor or …
prognosis when diagnosed at advanced stages. Surgical resection of the primary tumor or …
Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data
U Harkus, M Wankell, P Palamuthusingam… - Seminars in Cancer …, 2022 - Elsevier
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related deaths in the
world, and for patients with advanced disease there are few therapeutic options available …
world, and for patients with advanced disease there are few therapeutic options available …
Immunotherapy: current status and future perspectives
Hepatocellular carcinoma (HCC) has an increasing incidence and dismal prognosis, with
few systemic treatments approved, including several small molecule tyrosine kinase …
few systemic treatments approved, including several small molecule tyrosine kinase …